Cegedim

Activities: Media

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Digital

Why real-world data matters to patients

Healthcare systems globally are increasingly recognising the value of healthcare data. From developing improved care pathways to driving cost savings through data analytics, arguably the true value of healthcare data lies in patient outcomes
Regulatory

Power to the patient: The value of longitudinal data

Steve Bradley, Group Managing Director, Cegedim UK, outlines how data holds the key to better patient care
Finance

Cegedim Dendrite forms partnership with TAKE Solutions

Arrangement will enable Cegedim to expand its presence in India
Finance

Cegedim expands business in Switzerland

Acquires Swiss CRM and Direct Marketing businesses of IMS Health
Research & Development

Anne-Marie Masquelier joins Cegedim Strategic Data

Takes role of global medical research director
Media

Biopharma companies change market access strategies

Three-quarters of European biopharma firms see economic situation as key challenge
Subscribe now